大腸癌、血管增生、抗體分析

大腸癌、血管增生、抗體分析 是由出版商BioSeeker Group AB在2012年01月所出版的。 這份英文市場調查報告書包含4704 Pages 價格從美金5175起跳。

簡介

本報告針對大腸癌藥物開發目標策略、機制、目的、影響分類（血管增生）、複合領域（抗體）為焦點，提供各藥劑目的策略、複合策略競爭基準、臨床實驗與分析計劃，目錄介紹如下。

第1章 大腸癌

• 本報告範圍
• 以最佳治療結果與投資回收率為前提的大腸癌治療目標
• 新藥登場：開發階段分類大腸癌藥物目標策略
• 使用中的複合策略：複合策略分類競爭基準
• 臨床實驗與分析計劃
• 免責事項
• 藥物索引
• 企業索引
• 圖表

第2章 血管增生

• 本報告範圍
• 以最佳治療結果與投資回收率為前提的治療目標
• 新藥登場：開發階段分類血管增生藥物目標策略
• 使用中的複合策略：複合策略分類競爭基準
• 藥物影響與血管增生的適應癌症
• 臨床實驗與分析計劃
• 免責事項
• 藥物索引
• 企業索引
• 圖表

第3章 抗體

• 本報告範圍
• 以最佳治療結果與投資回收率為前提的治療目標
• 新藥登場：癌症抗體雙方管道的特定目標分析
• 抗體治療藥物適應癌症
• 臨床實驗與分析計劃
• 免責事項
• 藥物索引
• 企業索引
• 圖表

目錄

Abstract

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Table of Contents

Key Topics Covered:

Part I: Colorectal Cancer

• 5.1. The Scope of this Report 28
• 6. Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
• 7. Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
• 8. Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
• 9. Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
• 10. Disclaimer 1040
• 11. Drug Index 1041
• 12. Company Index 1050

• Figures: Includes 6 Figures
• Tables: Includes 242 Tables
• Total Number of Pages: 1,056

Part II: Angiogenesis

• 5.1. The Scope of this Report 35
• 6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (174 Drug Targets) 39-366
• 7. Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167 Drug Target Strategies and 239 Drugs) 367-437
• 8. Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies) 438-485
• 9. Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology (64 Cancer Indications) 486-643
• 10. Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148 Investigators) 644-1211
• 10. Disclaimer 1212
• 11. Drug Index 1213
• 12. Company Index 1221

• Figures: Includes 7 Figures
• Tables: Includes 300 Tables
• Total Number of Pages: 1227

Part III: Antibodies

• 5.2. The Scope of this Report 30
• 6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (225 Drug Targets) 36-319
• 7. The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Antibody Therapeutic Pipeline? (234 Drug Target Strategies and 441 Drugs) 320-383
• 8. Selecting Cancer Indications for Antibody Therapeutics (69 Different Cancer Indications) 384-499
• 9. Portfolio Planning: Competitive Benchmarking of Antibody Cancer Therapeutic Pipeline by Investigator (168 Investigators) 500-1268
• 11. Drug Index 1270
• 12. Company Index 1282

• Figures: Includes 5 Figures
• Tables: Includes 302 Tables
• Total Number of Pages: 1289

Featured Companies:

This Report Includes the Following Companies:

• A&G Pharmaceutical
• Abbott
• Abiogen
• Abraxis BioScience
• AC Immune
• Acceleron Pharma
• Access
• ACT Biotech
• Active Biotech
• Adherex
• Advanced Cancer Therapeutics
• Advantagene
• Advaxis
• Advenchen
• Aeterna Zentaris
• Affibody
• Affimed Therapeutics
• Agennix
• Aida Pharmaceuticals
• Alchemia
• Alethia Biotherapeutics
• Alexion
• Allos Therapeutics
• Alnylam
• AlphaVax
• Alseres Pharmaceuticals
• Ambit Biosciences
• Ambrilia Biopharma
• Amgen
• Amphora
• Anavex Life Sciences
• Angiogen
• Angiogenex
• Angstrom Pharmaceuticals
• Ansaris
• Antisense Pharma
• Antisoma
• Aphios
• Apotex
• Arana Therapeutics
• Ariad
• Arno Therapeutics
• ArQule
• Array BioPharma
• Astellas
• Astex Therapeutics
• AstraZeneca
• Attenuon
• Austrianova
• AVEO
• AVI BioPharma
• Bayer
• Betapharma
• BioAlliance Pharma
• BioAxone
• Biocompatibles
• Biogen Idec
• BioInvent
• BioNumerik
• Biosceptre
• Biotecnol
• BioVex
• Boehringer Ingelheim
• Bolder BioTechnology
• Bristol-Myers Squibb
• BTG
• Can-Fite BioPharma
• Cancer Advances
• Cancer Research Technology
• CDG Therapeutics
• Celator Pharmaceuticals
• Celecure
• Celera
• Celgene
• Cell Therapeutics
• CellCeutix
• Celldex Therapeutics
• Cellmid
• Celsion
• Celtic Pharma
• Center of Molecular Immunology
• Cephalon
• CG Therapeutics
• ChemGenex Pharmaceuticals
• ChemoCentryx
• Chemokine Therapeutics
• China Sky One Medical
• Choongwae
• Circadian Technologies
• Clavis Pharma
• Cosmo Pharmaceuticals
• Cue Biotech
• CuraGen
• CureTech
• Curis
• Cyclacel
• Cylene Pharmaceuticals
• Cynvec
• CytImmune Sciences
• Cytochroma
• Cytokinetics
• Daiichi Sankyo
• Dainippon Sumitomo Pharma
• Deciphera Pharmaceuticals
• Dendreon
• Dyax
• Dynavax Technologies
• EGEN Inc
• Eisai
• Elan
• Eli Lilly
• Endocyte
• Enkam Pharmaceuticals
• EntreMed
• Enzon
• Epeius Biotechnologies
• EpiCept
• Etubics
• Exelixis
• ExonHit Therapeutics
• Facet Biotech
• FasTrack Pharmaceuticals
• Five Prime Therapeutics
• GammaCan
• Genentech
• Genmab
• Genta
• GenVec
• Genzyme
• Gilead Sciences
• GlaxoSmithKline
• Gliknik
• GlycoGenesys
• Gradalis
• Green Cross
• Heidelberg Pharma
• Hoffmann-La Roche
• Human Genome Sciences
• Hy BioPharma
• Idera Pharmaceuticals
• IkerChem
• ImClone Systems
• ImmunoCellular Therapeutics
• Immunocore
• ImmunoGen
• Immunomedics
• ImmuPharma
• Incyte Corporation
• Innate Pharma
• InNexus Biotechnology
• Inovio
• Insys Therapeutics
• Introgen Therapeutics
• Ipsen
• ISA Pharmaceuticals
• Isis Pharmaceuticals
• ISU ABXIS
• Ivy Medical Chemicals
• Jennerex Biotherapeutics
• Johnson & Johnson
• KAI Pharmaceuticals
• Karus Therapeutics
• Kiadis
• Kirin Pharma
• Kringle Pharma
• Kyowa Hakko Kirin
• Labopharm
• Lee' s Pharmaceutical
• Leo
• Lorus Therapeutics
• MacroGenics
• MAT Biopharma
• Meda
• Medarex
• MediGene
• MedImmune
• Menarini
• Merck & Co
• Merck KGaA
• Merrimack
• Mersana Therapeutics
• MethylGene
• Micromet
• Mitsubishi Tanabe Pharma
• MolMed
• Mologen
• Morvus Technology
• Nektar Therapeutics
• Neovacs
• Nerviano Medical Sciences
• NewSouth Innovations
• NicOx
• Nippon Kayaku
• Northwest Biotherapeutics
• Novartis
• Novelix
• Nycomed Pharma
• Oasmia
• OncoGenex Pharmaceuticals
• OncoMed
• Onconova
• OncoTherapy Science
• Oncothyreon
• Oncozyme Pharma
• Onyvax
• Orca Therapeutics
• Orchestra Therapeutics
• OSI Pharmaceuticals
• Oxford BioMedica
• OXiGENE
• Paladin Labs
• PanaGin
• Pepscan Therapeutics
• PepTx
• Peregrine Pharmaceuticals
• Pfizer
• Pharmaclon
• Pharmacopeia
• Pharmacyclics
• PharmaGap
• PharmaMar
• Pharmexa
• Pharminox
• Philogen
• PhiloGene
• Pierre Fabre
• Plexxikon
• POZEN
• Prima Biomed
• Pro-Pharmaceuticals
• Progen
• Progenics Pharmaceuticals
• Protein Sciences
• Protherics
• PTC Therapeutics
• Receptor BioLogix
• Regeneron
• Rexahn
• Rigel
• Sanofi-Aventis
• Santaris Pharma
• Sareum
• Scancell
• SciClone Pharmaceuticals
• Seattle Genetics
• Semafore Pharmaceuticals
• Shire
• Sigma-Tau
• Simcere Pharmaceuticals
• Spear Therapeutics
• Spirogen
• SRI International
• SuperGen
• Supratek Pharma
• Switch Pharma
• SynDevRx
• Synta Pharmaceuticals
• Taiho
• Takeda
• Talon Therapeutics
• Targa Therapeutics
• Targepeutics
• Tau Therapeutics
• Taxolog
• Telik
• Teva
• Thallion Pharmaceuticals
• The Genetics Company
• Therion Biologics
• ThromboGenics
• Tigris Pharmaceuticals
• Titan Pharmaceuticals
• ToolGen
• TopoTarget
• Tracon Pharmaceuticals
• Transgene
• Trion Pharma
• UCB
• Vaccinex
• VBL Therapeutics
• Vertex Pharmaceuticals
• Vical
• Wilex
• VioQuest Pharmaceuticals
• Viragen
• Viralytics
• Wyeth
• Xerion
• Xoma
• Yakult Honsha
• YM BioSciences

Featured Drugs:

A Shortlist of Drugs Included are:

• 131I-tositumomab
• abagovomab
• adecatumumab
• aflibercept
• afutuzumab
• AGS-1C4D4
• AGS-PSCA
• ALD-518
• alemtuzumab
• ALXN-6000
• AME-133
• AMG-479
• Angiozyme
• apatinib
• Apomab
• ARQ-197
• axitinib
• bevacizumab
• BIBF-1120
• BIIB-022
• blinatumomab
• BMS-663513
• brentuximab vedotin
• brivanib alaninate
• capecitabine
• catumaxomab
• cediranib
• cetuximab
• cilengitide
• cixutumumab
• CNTO-328
• CNTO-888
• conatumumab
• CT-011
• daratumumab
• denosumab
• DI-17E6
• doxifluridine
• elotuzumab
• EMD-273063
• endostatin
• enzastaurin hydrochloride
• epratuzumab
• epratuzumab-Y90
• ertumaxomab
• everolimus
• F-50035
• farletuzumab
• figitumumab
• fosbretabulin tromethamine
• fresolimumab
• G-250
• galiximab
• GDC-0449
• HBP-347
• I-131-labetuzumab
• ibritumomab tiuxetan
• IMC-3G3
• IMGN-901
• INGN-241
• inotuzumab ozogamicin
• interferon gamma
• intetumumab
• IPH-2101
• ipilimumab
• iratumumab
• irinotecan bead
• irinotecan hydrochloride
• KW-0761
• L19-SIP
• linifanib
• lintuzumab
• LIP-131I
• lucatumumab
• lumiliximab
• lymphomun
• mapatumumab
• matuzumab
• MCS-110
• MDX-1106
• MGN-1703
• midostaurin
• milatuzumab
• MM-111
• MORAb-009
• motesanib diphosphate
• naptumomab estafenatox
• natalizumab
• necitumumab
• nimotuzumab
• ocrelizumab
• ofatumumab
• Onyvax-105
• oregovomab
• OTS-102
• panitumumab
• PAT-SC1
• patupilone
• pazopanib hydrochloride
• perifosine
• pertuzumab
• PF-4856884
• raltitrexed
• ramucirumab
• regorafenib
• RG 3638
• RG-1507
• ridaforolimus
• rilotumumab
• rituximab
• robatumumab
• sorafenib tosylate
• sunitinib malate
• talactoferrin alfa
• tegafur + uracil
• tegafur + uracil + leucovorin
• Tenarad
• thymalfasin
• tigatuzumab
• tipifarnib
• tocilizumab
• trastuzumab
• tremelimumab
• TRU-016
• TS-1
• tucotuzumab celmoleukin
• vandetanib
• veltuzumab
• volociximab
• XL-184
• YS-110
• yttrium Y 90 clivatuzumab tetraxetan
• zalutumumab
• Zemab

相關商品

癌症相關市場調查報告書

膀胱癌相關的各種合作趨勢:2007-2012年
Bladder Cancer Partnering 2007-2012
價格 : US $ 995
出版日期 : 2012年05月

腦瘤相關的各種合作趨勢:2007-2012年
Brain Cancer Partnering 2007-2012
價格 : US $ 995
出版日期 : 2012年05月

乳癌相關的各種合作趨勢:2007-2012年
Breast Cancer Partnering 2007-2012
價格 : US $ 1695
出版日期 : 2012年05月

BioSeeker Group AB發行的製藥相關市場調查報告書

癌症的蛋白激脢治療上的競爭分析

Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

價格 : US $ 4425

出版日期 : 2012年05月

分析工具：癌症治療的蛋白激脢抗化劑

Analytical Tool - Protein Kinase Inhibitors in Oncology

價格 : US $ 6674

出版日期 : 2012年05月

乳癌、大腸癌、蛋白質激酶抑制劑分析

Triple Analysis: Breast Cancer, Colorectal Cancer and Protein Kinase Inhibitors

價格 : US $ 5175

出版日期 : 2012年05月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!